BOT 0.00% 38.0¢ botanix pharmaceuticals ltd

BOT - Anything but charting, page-8739

  1. 15 Posts.
    lightbulb Created with Sketch. 3
    Probably too late in the piece, but I wonder if selling the rights to Sofdra to different regions for an upfront payment and ongoing royalties may have helped avoid a potential CR for sales and marketing expenses.

    DMX seems to be applying this strategy and it isn’t hurting their SP…I think the be middle east deal was only $750K but %30 on the backend. If BOT could find a partner to commit to a higher upfront investment for lower royalty rates, happy days.

    First BOT post so be gentle.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.